Environmental Clean Technologies secures global MXene license from Drexel University

Environmental Clean Technologies (ASX:ECT) has announced that Xenica, Inc., a wholly owned subsidiary of its acquisition target Xenica Pty Ltd, has secured a global, non-exclusive licence from Drexel University. This licence permits the manufacture, use, import, and sale of MXenes for specified commercial applications, broadening Xenica's market scope beyond defense into various industrial sectors.

Drexel University, which discovered MXenes in 2011 and holds key patents on MXene compositions, has granted this worldwide, non-exclusive licence. It allows Xenica to produce, use, import, and sell MXene materials for commercial purposes, with exceptions for electromagnetic interference shielding, dialysis, biosignal electrodes, antennas, infrared shielding, and military uses. Military applications are separately covered under an existing sublicence with MXene Inc. The licence will remain in effect until the expiration of the underlying patent rights, with Drexel receiving royalties on future sales, as noted in the filing.

According to the filing, once the Xenica acquisition is finalized, ECT's MXene platform will encompass an exclusive Rice University Flash Joule Heating licence for MXene production, access to Metallium Ltd's commissioned Gator Point FJH reactor under a Research & Development and Engineering Agreement, an initial defense-compatible MAX Phase precursor supply, the MXene Inc. military end-use sublicence, and the newly obtained Drexel University commercial licence. The filing also mentioned that the first MXene material has been produced, with repeatability, validation, and sampling as the next steps towards customer acceptance and sales.

The filing outlines licensed commercial applications such as energy storage, including supercapacitors and fast-charging batteries, industrial coatings and composites (excluding electromagnetic interference shielding), PFAS water filtration, and other uses covered by the licence. Defense remains ECT's primary commercialization focus. The company has detailed a sequence of next steps: completing the Xenica acquisition, demonstrating repeatable FJH MXene production, validating material quality through independent characterization, providing samples and advancing customer qualification starting with defense clients, and establishing production economics alongside securing commercial agreements. The filing notes that any revenue is contingent on successful scale-up, material meeting customer specifications, customer qualification, and commercial contracts.